Autophagy is essential for cellular homeostasis and when deregulated this survival mechanism has been associated with disease development. Inhibition of autophagy initiation by inhibiting the kinase ULK1 (Unc-51-like autophagy activating kinase 1) has been proposed as a potential cancer therapy. While inhibitors and crystal structures of ULK1 have been reported, little is known about the other closely related kinase ULK2 (Unc-51-like autophagy activating kinase 2). Here, we present the crystal structure of ULK2 in complex with ATP competitive inhibitors. Surprisingly, the ULK2 structure revealed a dimeric assembly reminiscent of dimeric arrangements of auto-activating kinases suggesting a role for this association in ULK activation. Screening of a kinase focused library of pre-clinical and clinical compounds revealed several potent ULK1/2 inhibitors and good correlation of inhibitor-binding behavior with both ULK kinases. Aurora A was identified as a major off-target of currently used ULK1 inhibitors. Autophagic flux assays demonstrated that this off-target activity by strongly inducing autophagy in different cellular systems conferred an additional layer of complexity in the interpretation of cellular data. The data presented here provide structural models and chemical starting points for the development of ULK1/2 dual inhibitors with improved selectivity for future exploitation of autophagy inhibition.
Autophagy is an essential mechanism for the survival of eukaryotic cells upon low nutrient availability and prolonged starvation, and at the basal level serves a recycling role for cellular components through degradation of a wide range of substrates from proteins to organelles required for maintaining cellular homeostasis [1,2]. This catabolic process constitutes a multi-step activation and maturation mechanism involving the assembly of large signaling complexes of more than 40 conserved proteins [3–5]. During autophagy, cytoplasmic contents are sequestered within the developing double-membraned phagophore, from which the completed autophagosome then fuses with the lysosome leading to degradation of the contents with subsequent release of free amino acids and other byproducts. In the past few decades, the importance of this process in human health has been demonstrated by many studies, revealing two contradictory faces of autophagy. While exerting a protective role against cellular stress  and development of many diseases including cancer, neurodegenerative and hyperinflammatory disorders [7–11], autophagy appears to strongly contribute to the progression of cancer, such as KRAS-driven tumors, to survive a nutrient-deprived microenvironment and therapeutic stress [12–19]. Because of the latter, autophagy inhibition may provide a strategy to inhibit tumor cell growth and to improve the efficacy of cancer treatments [20,21]. However, the potential benefits of the therapeutic targeting of autophagy remain controversial due to conflicting context-dependent roles of this process in cancer development and progression [22–24], and therefore there is a need for a better understanding on the complexity of its regulation.
Initiation of autophagy requires the formation of an early regulatory complex centered on Unc-51-like autophagy activating kinase 1 (ULK1), a serine/threonine kinase homolog of yeast ATG1 (autophagy-related protein 1), that recruits its binding partners ATG13 (autophagy-related protein 13), RB1CC1 (retinoblastoma 1-inducible coiled-coil protein 1, also known as FIP200) and ATG101 (autophagy-related protein 101) [25–27]. mTOR inhibition results in the activation of early autophagy, a process that is counteracted by the metabolic sensor kinase AMPK linking these two key pathways regulating cellular metabolism. In humans, ULK1 co-operates in regulating autophagosome assembly with a closely related homolog, Unc-51-like autophagy activating kinase 2 (ULK2), both of which share a high degree of conservation of the domain architecture including an N-terminal catalytic kinase, extensive middle linker and C-terminal domain . These two kinases have an overlapping function in autophagy induction under nutrient deprivation [29,30]. As a consequence, complete knock-outs of both kinases in mouse embryonic fibroblasts are required for the inhibition of autophagy [30–32]. Nevertheless, some non-overlapping roles of ULK2 have been demonstrated recently, which might potentially relate to context-dependent requirements and the genetic background of specific cell types [33–35].
With essential roles in diseases [36–40], ULK1 has been identified as an attractive target for inhibition of the autophagy pathway. Crystal structures of ULK1 provide insights into the druggable pockets of this kinase , leading to the development of several inhibitors, including SBI-0206965 , MRT67307, MRT68921  and recently ULK-101 . The efficacies of these small molecules towards autophagy suppression have been demonstrated, providing an initial proof of concept for this kinase as a potential chemotherapeutic target. However, while published inhibitors are potent inhibitors of ULK1, currently available inhibitors are not entirely selective for ULK1. Furthermore, to date, little is known regarding the role of the closely related isoform ULK2, which according to its sequence and domain conservation would also need to be targeted for the pharmacological modulation of autophagy initiation. The lack of information regarding the structural, biochemical and biological properties of ULK2, therefore, may limit our understanding of potential beneficial effects and applications of the use of these ULK1 inhibitors for suppression of autophagy.
In the present study, we report the first structure of ULK2, revealing not only similarity of its kinase domain and ligand-binding properties to that of the family-related ULK1, but also an interesting activation segment domain exchange dimerization that potentially represents a structural mechanism for autophosphorylation and activation of these two kinases. Screening against a diverse set of kinase inhibitors showed similar inhibitor-binding properties of both ULK isoforms and demonstrated unexpectedly potent hits of diverse inhibitors developed for other kinases. The binding of these compounds is consistent with the flexible nature of the ULK1/2 kinase pockets, whereas notably, Aurora kinase activity seems a liability of current ULK1 tool compounds and many of the identified inhibitors in our screen. Structural and functional consequences of this unexpected SAR (structure–activity relationship) similarity are discussed.
Protein expression and purification
All ULK1 (1-283) and ULK2 (1-276) kinase domains were recombinantly expressed as fusion proteins incorporating either His6 or His6-Sumo tags at the N-termini. Briefly, E. coli cultured in TB media was initially grown at 37°C until reaching the OD600 of 1.6–1.8, before subsequently cooled to 18°C, and at OD600 of 2.6–3.0 was induced with 0.5 mM IPTG overnight. Harvested cells were lysed by sonication, and the proteins were purified using Ni2+-affinity chromatography. The eluted proteins were buffer exchanged into 30 mM Tris (pH 7.5), 300 mM NaCl, 0.5 mM TCEP and 10% glycerol, and their expression tags were cleaved using SENP1 or TEV. If necessary, autophosphorylation was performed during proteolysis by supplementing ATP and MgCl2 at 10- and 20-fold molar excess, respectively. The cleaved proteins were passed through Ni2+ beads and further purified by size exclusion chromatography. The pure proteins in 25 mM Tris (pH 7.5), 100 mM NaCl, 10% glycerol were stored in −80°C.
Crystallization and structure determination
The recombinant ULK1 and ULK2 at ∼10–12 mg/ml were mixed with inhibitors at ∼2- to 3-fold molar excess prior to crystallization using the sitting drop vapor diffusion method at 20°C. Crystallization conditions are summarized in Supplementary Table S2. Viable crystals were cryo-protected using mother liquor supplemented with 25% glycerol or 22% ethylene glycol, flash frozen in liquid nitrogen and tested for their X-ray diffraction quality at Bessy II. Diffraction data were collected at Swiss Light Source or Diamond and were processed and scaled with iMosflm  or XDS  and aimless , respectively. Initial structure solutions were obtained by molecular replacement using Phaser  and the co-ordinates of previously published ULK1 . Iterative cycles of manual model rebuilding alternated with structure refinement were performed using Coot  and REFMAC , respectively. Final structures were verified for their geometric correctness using MolProbity . The data collection and refinement statistics are summarized in Supplementary Table S2.
Thermal shift assays
Recombinant kinase domains of ULK1, ULK2 and Aurora A at 2 µM in 10 mM HEPES (pH 7.5) and 500 mM NaCl were mixed with 10 µM inhibitors. Temperature-dependent protein unfolding profiles were measured using a Real-Time PCR Mx3005p machine (Stratagene). The data evaluation and melting temperature calculation were performed as described previously [52,53].
All isothermal calorimetry (ITC) experiments were performed using NanoITC (TA Instruments) at 25°C in the buffer containing 25 mM Tris (pH 7.5), 200 mM NaCl, 0.5 mM TCEP and 10% glycerol. The protein at ∼0.12 mM was titrated into the reaction cell containing the inhibitors. The heat of binding was integrated, corrected and fitted to an independent single binding site model based on the manufacture protocol, from which thermodynamics parameters (ΔH and TΔS), equilibrium association and dissociation constants (Ka and KD) and stoichiometry (n) were calculated.
Autophagic flux assays in RPE1
RPE1 cells (1500 cells/well in 50 µl DMEM/F12, 10% FBS, 1% penicillin/streptomycin) stably expressing the GFP–LC3–RFP–LC3ΔC autophagic flux reporter  were seeded in black, optically clear bottom 384-well plates (Nunc) and grown for ∼18 h. Plates were subsequently placed and monitored in the IncuCyte® (Sartorius). After the first scan (0 h), an additional 50 µl media containing compounds at 2× final concentration were added. Cells were scanned continuously during the measuring time-window for phase contrast and fluorescence to obtain information about confluency and autophagy flux, respectively.
Autophagic flux assays in leukemia cell lines
Human acute myeloid leukemia (AML) cell lines MV4-11 and MOLM-14 (purchased from Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH [DSZMZ]) stably expressing a GFP–LC3B–mCherry flux reporter  after lentiviral transduction similarly as previously described  were cultured in RPMI 1640 medium (Gibco) supplemented with 10% FBS (Sigma–Aldrich) and 1% penicillin/streptomycin. Cell lines were cultured at 37°C with 5% CO2 in a humidified Heracell 150i incubator (Thermo Fisher Scientific) and regularly confirmed by PCR to be free of mycoplasms. For dose–response measurements, cells were washed once with PBS (Gibco) on the day prior to the experiment and cultured in fresh medium at a density of 0.5 × 106 cells/ml. On the next day, cells were washed again, resuspended in fresh medium, seeded at a density of 0.5 × 106 cells/ml and treated with individual compounds or DMSO as a vehicle control. Fluorescence mCherry (G610/20) and eGFP (B530/30) signal intensities were measured by flow cytometry on a BD LSRFortessa (BD Biosciences) flow cytometer after 8 and 24 h following treatment. At least 10 000 events were measured for each sample. Autophagic flux was quantified by ratiometric single-cell eGFP/mCherry values, aggregated per sample by the arithmetic mean, and normalized to DMSO vehicle controls. Experiments were performed in duplicates.
For the ULK1 kinase assay, the 5 µl kinase reaction was performed using 2 µg/ml recombinant human ULK1 protein (1-649, SignalChem #U01-11G) and 80 µg/ml myelin basic protein (MBP, Sigma–Aldrich #M1891) in the presence of 25 µM ATP (Sigma–Aldrich A7699). For ULK2 kinase assay, the 5 µl reaction was performed using 4 µg/ml recombinant human ULK2 protein (1-478, SignalChem #U02-11G) and 80 µg/ml MBP in the presence of 25 µM ATP. Compounds were tested in triplicate in a 16-dose IC50 mode with three-fold serial dilution and a starting dose of 30 µM. Staurosporine, a non-selective protein kinase inhibitor, was used in the assay as a positive control. Three separate experiments were carried out.
Results and discussion
ULK1 and ULK2 share a conserved overall kinase structure
Sequence analysis of ULK1 and ULK2 revealed that the kinase domain of both proteins shared a high sequence identity of ∼75%, and apart from an N-terminal extra 7-amino acid extension in ULK1, all catalytic elements essential for kinase activities were well conserved (Supplementary Figure S1). To provide structural models, we crystallized both kinases and determined the high-resolution crystal structures of ULK1 harboring the E37A, K38A surface entropic mutation doubly phosphorylated at S87 and the activation loop T180 (Figure 1A) and the activation loop T173D ULK2 mutant (Figure 1B). Both ULK1 and ULK2 were highly resembled in overall topology, adopting the typical bilobal kinase architecture similar to the previously published ULK1 structural model  (Figure 1; Supplementary Figure S1). However, two distinct structural differences were observed at the regulatory helix αC and the activation segment. In ULK1 harboring a phosphorylated activation loop at T180, these two regulatory elements assumed an active conformation, similar to the ULK1 structure reported previously , whereas the ULK2 structure displayed a distorted αC and an elongated activation segment, likely depicting an inactive conformation despite containing the activation loop T173D phosphomimetic mutation. Other less dramatic conformational differences were apparent for the flexible β6–β7 insertion loop (interlobe loop) that shared low sequence identity and the β4–β5 loop of which the unexpected non-regulatory autophosphorylation at S87 in ULK1 caused small perturbation on the N-lobe β-sheet integrity. Nonetheless, apart from these alterations, both structures superimposed well, demonstrating a high structural conservation between these two key autophagy kinases (RMSD of ∼1.3 Å for 220 Cα atoms, excluding the αC-helix and activation segment).
Overall structure of ULK1 and ULK2.
Activation loop exchange enables dimeric assembly in ULK2 structure
Analyses of the crystal structures revealed another unexpected feature in ULK2. The ULK2 catalytic domain engaged in a dimeric assembly, which was in contrast with the typically monomeric ULK1. The two protomers of the ULK2 kinase domain associated in a face-to-face fashion with the αC and the activation segment packed at the two-fold dimeric interface, explaining the unusual conformations of these two structural elements (Figure 2A; Supplementary Figure S2). A striking feature in the dimer was the exchange of the activation segment, a configuration involving a protrusion of the segment from one subunit into the substrate-binding groove fenced by the αF and αG of the neighboring subunit in the pair. Despite a few direct inter-molecular interactions formed (Figure 2B), this extended conformation covers a large interface contact area indicating a potential driver for this oligomerization.
Domain-exchanged activation segment dimerization in ULK1/2.
We were interested whether the dimer observed in the ULK2 crystal structure is physiologically relevant or may serve a regulatory function. Comparative structural analyses revealed that this face-to-face, domain-exchanged activation segment dimerization in ULK2 highly resembled conformations observed previously in other kinases, such as SLK (STE20-like serine/threonine-protein kinase ), LOK (lymphocyte-oriented kinase), DAPK3 (death-associated protein kinase 3) and CHK2 (checkpoint kinase 2) [56,57] (Figure 2C–E; Supplementary Figure S2). Since the dimeric exchanged activation segment arrangement has been proposed as a mechanism for trans-activation by autophosphorylation of the activation segment at non-consensus sites [56,58], we, therefore, postulated a similar role for this conformation in ULK1/2. This hypothesis was supported by (i) a non-consensus sequence present in the ULK1/2 activation segment, exemplified by T180/173 and C182/175 that did not match the preferred serine and bulky hydrophobic amino acids flanking the phosphorylation sites in consensus substrate sequences [42,59] (Figure 2E), and (ii) the presence of the activation loop helix (αAL) adaptor which has been shown to be necessary for positioning the activation segment threonine into the kinase substrate site (T180 and T173 in ULK1 and ULK2, respectively, equivalent to S189 in SLK ) (Figure 2B–E). In addition, although this self-association stabilized in the crystals is typically a transient property in solution , we were able to detect dimerization of ULK2 in analytical gel filtration for both wild-type, non-phosphorylated ULK2 and, to a lesser extent, wild-type ULK1 (Figure 2F). The functional consequence of this interaction was demonstrated by the ability of the two kinases to autophosphorylate upon incubating with ATP-MgCl2 (Figure 2G), from which the location of the phosphothreonine at the corresponding sites in ULK1/2 was confirmed by tryptic digestion mass spectrometry (data not shown). This cumulative evidence potentially suggested therefore that ULK1/2 may possess an ability for (transient) dimeric assembly and utilize the shared activation segment domain-exchanged mechanism for trans-autophosphorylation of their specific activation loop threonine residues for kinase activation. Nevertheless, the roles of the distorted, inactive αC-helix conformation observed in the ULK2 structures (Figure 1B) in its trans-activation mechanism remain unclear.
Conservation of inhibitor binding in ULK1 and ULK2
The high sequence and structural similarity between ULK1 and ULK2 prompted us to next investigate whether these kinases also share similar inhibitor-binding properties. A set of 384 known kinase inhibitors, which included also some previously developed ULK1 inhibitors, such as SBI-0206965 , MRT67307 and MRT68921 , were screened against the kinases using thermal stability-shift assays . As expected, a good correlation of the temperature shift (ΔTm) profiles was observed across this set of compounds for the ULK1 and ULK2 catalytic domains indicating that both kinases exhibit similar inhibitor-binding behavior (Figure 3A). Among the three ULK1 inhibitors, MRT68921 resulted in the highest Tm shift for both kinases (ΔTm of 12.1 and 14.8°C for ULK1 and ULK2, respectively), while the others showed only moderate stabilization with similar ΔTm values in a range of 6.5–9.8°C (Figure 3A; Supplementary Table S1).
Inhibitor screening for ULK1 and ULK2.
Interestingly, there were 18 additional, structurally diverse compounds that also exhibited strong Tm shifts with similar levels to that of the ULK1 inhibitor SBI-0206965 and MRT67307 as indicated by ΔTm of >6°C, typically suggesting a binding affinity in the sub-micromolar range  (Figure 3A; Supplementary Table S1). Structural analyses reveal that most of these compounds share two generic hinge-binding motifs of either 2-aminopyrimidine or 2-oxindole, yet other scaffolds are also evident (Figure 3B). Nonetheless, the large number of hits from this set was rather unexpected considering the SARs that presumably optimized them for their specific kinase targets. For example, the activities of many specific Aurora kinase inhibitors, such as hesperadin, PF-03814735 and PHA-680632, towards ULK1/2 were surprising considering that they belong to two distinct kinase subfamilies. To investigate whether ULK1/2 and Aurora A might exhibit a similar preference towards certain inhibitors, we compared the Tm shifts of ULK1 and Aurora A and observed good correlations for some compound classes (Figure 3C). Nearly all inhibitors that bound ULK1 also interacted strongly with Aurora A, and this applied also to the ULK tool inhibitors SBI-0206965, MRT67307 and MRT68921. However, this trend was not observed for all Aurora A inhibitors that have been screened, suggesting inhibitor class dependent cross-reactivity. For example, the Aurora A inhibitor alisertib, a pyrimidobenzazepine, that enters clinical trials was inactive against ULK1 and ULK2.
To validate the results from the Tm shift assays, we performed ITC to measure binding affinities of some ULK1/2 hits in solution. All selected inhibitors showed KD values for ULK1, ULK2 and Aurora A in the low nanomolar range in agreement with the observed Tm shifts and the measured in vitro IC50 values (Figure 3D–F; Table 1).
|Average IC50 (M)||SEM (M)||Average IC50 (M)||SEM (M)|
|MRT67307||3.82 × 10−8||7.39 × 10−9||9.23 × 10−8||2.66 × 10−8|
|MRT68921||1.70 × 10−8||4.52 × 10−9||2.08 × 10−8||4.58 × 10−9|
|SBI-0206965||3.06 × 10−7||1.59 × 10−7||3.88 × 10−6||9.02 × 10−7|
|Average IC50 (M)||SEM (M)||Average IC50 (M)||SEM (M)|
|MRT67307||3.82 × 10−8||7.39 × 10−9||9.23 × 10−8||2.66 × 10−8|
|MRT68921||1.70 × 10−8||4.52 × 10−9||2.08 × 10−8||4.58 × 10−9|
|SBI-0206965||3.06 × 10−7||1.59 × 10−7||3.88 × 10−6||9.02 × 10−7|
Increasing affinities corresponded well with higher ΔTm values. MRT68921, for example, was the most potent inhibitor in the Tm assay with a KD of 3.4 and 4.9 nM for ULK1 and ULK2, respectively, and the affinities of ∼17–160 nM for the others correlated well with their lower ΔTm values in the 6–10°C region (Figure 3E). An exception was noted for the moderate affinities for SBI-0206965, which correlated well with the ΔTm values and matched the reported IC50 value for ULK2 . However, our in vitro KD for ULK1 was ∼7-fold smaller compared with the previously reported potency on ULK1 (IC50 of 108 nM ), yet consistent with the micromolar activities recently reported in cellular systems . Nonetheless, regardless of their potencies most of these typical type-I inhibitors exhibited similarly entropically favorable thermodynamic signatures for their binding in both kinases (Figure 3F).
Structural insights into the common binding pockets of ULK1 and ULK2
To provide structural information of the inhibitor-binding modes, we determined high-resolution crystal structures of four kinase inhibitor complexes, including ULK1 with PF-03814735, and ULK2 with MRT68921, MRT67307 and hesperadin (Figure 4A). All inhibitors exhibited typical type-I interactions with the canonical hydrogen bonds formed by the 2-aminopyrimidine and 2-oxindole scaffolds with the hinge backbones. However, small differences were noted in their binding positions such as the deep protrusion of 2-oxindole towards the back pocket targeting the residue at the gatekeeper +1 (GK+1) position, which was in contrast with interactions formed by 2-aminopyrimidine that was shifted outward to interact instead with the gatekeeper +3 position (GK+3) residue (Figure 4B). In comparison, all of these positions have been exploited previously for an accommodation of the alternative 3-aminopyrazole hinge-binding motif . These data suggest, therefore, a potential capacity for ULK1/2 in accepting diverse type-I hinge-binding scaffolds, which is supported by the high hit rates in the small focused library screen.
Crystal structures of ULK1/2-inhibitor complexes.
Detailed analyses of the inhibitor-complexed structures provided further insights into the characteristics of the ULK1/2-binding sites (Figure 4A–C). First, we observed some degree of flexibility of the methionine gatekeeper (M92 and M85 in ULK1 and 2, respectively), suggesting a certain degree of plasticity of the back pocket when accommodating bulky hydrophobic moieties, such as cyclopropane in MRT67307 and MRT68921, trifluoromethyl of PF-03814735 or even bulkier oxindole of hesperadin as well as iodide and cyclobutane reported to occupy this position previously [41,60]. Second, the binding of all inhibitors induced an ‘outward’ conformation of the phenylalanine at the tip of the P-loop (F27 and F20 in ULK1 and 2, respectively), creating an unusually large binding pocket within the ribose and phosphate binding pocket. Evidently, this cavity was exploited by diverse decorating groups of the co-crystallized inhibitors which filled different space leading to different bound water patterns and engaging slightly different interactions with the kinases (Figure 4A,C). A large pocket was noted in the solvent-exposed region adjacent to the hinge; however, the interactions of most inhibitors in this region were rather limited. Interestingly, we observed a unique trajectory of the benzopiperidine of MRT68921 towards the negatively charged, aspartate-rich region in proximity to the αD, leading to a direct contact with D95 (Figure 4B). This distinct interaction might explain the ∼8-fold increase in affinity of MRT68921 in comparison with the highly related MRT67307.
Overall, these structures present unusually large binding pockets in ULK1 and ULK2 suggesting a high degree of plasticity of these kinase catalytic domains, which was in agreement with the unexpectedly large number of diverse, highly decorated hits identified from the screened kinase inhibitor set. In addition, both kinases employ a similar set of residues that line the binding sites, supporting the close correspondence of their inhibitor-binding behaviors (Figure 4A,C). Such undistinguishable characteristics of the pockets shared between ULK1 and ULK2 suggest therefore that both kinases can be efficiently co-targeted by an inhibitor with highly similar interactions and binding properties, which is supported by similar affinities of known ULK1 inhibitors and the large number of identical hits identified. As efficient inhibition of both ULK1 and ULK2 is required for efficient inhibition of autophagy, our structural data suggest that selective dual-targeting chemical probes can be developed for these two kinases.
Modulation of autophagy by current ULK inhibitors
Having demonstrated the high similarity of inhibitor-binding characteristics in ULK1 and ULK2, the current ULK1 tool compounds may possess sufficient favorable property for achieving inhibition of autophagy at initiation through these kinases. However, cross-activities on off-targets, as demonstrated for example on Aurora A (Figure 3), could lead to more complex effects on autophagy modulation. To assess this, we exploited an LC3-based GFP/mCherry or GFP/RFP fluorescence assay to measure autophagic flux  following treatment with three ULK1 inhibitors, SBI-0206965, MRT67307 and MRT68921, and the highly selective Aurora inhibitor alisertib (Figure 5A). First, using an RPE cell model  under conditions of normal growth media, we observed surprisingly that all inhibitors moderately induced autophagy as observed by the decrease in GFP/RFP ratio throughout the measured time course (Figure 5B,C). Interestingly, all four inhibitors shared a concentration-dependent autophagy induction pattern to that of alisertib (Figure 5C). However, differences in autophagic flux were noticed for the most potent ULK1/2 inhibitor MRT68921, of which the induction effects were less pronounced and reversed at higher inhibitor concentration which might potentially be due to the anticipated ULK1/2 inhibition.
Complex cellular effects of ULK1/2 inhibitors on autophagy modulation due to off-target effects.
We next performed these assays in two leukemia cell lines, MV4-11 and MOLM-14 (Figure 5D; Supplementary Figure S3). Consistently, we observed autophagy induction for SBI-0206965, MRT67307 and alisertib in a similar dose-dependent manner as seen in RPE1 cells. Interestingly, MRT68921 exhibited once again a unique pattern among the tested inhibitors. While causing initial induction of autophagy at lower concentrations, a reverse of fluorescence ratios was evident at a higher concentration of >100 nM, suggesting autophagy inhibition at higher inhibitor concentration.
Overall, the concentration- and time-dependent autophagic flux profiles of the tested inhibitors likely indicates that despite potently inhibiting both ULK1 and ULK2, their off-target activities, such as Aurora A inhibition, induced autophagy, most likely caused by cytotoxicity or cellular stress. This clearly complicates readouts on autophagic flux. The macroautophagy induction constitutes a cytoprotective survival process observed in several cancer entities upon cytotoxic treatment [13,15]. For mechanistic studies, the development of more selective ULK1/2 inhibitors with minimal off-target effects is needed for determining the value of ULK1/2 inhibition as a therapeutic target in a definitive manner. Nevertheless, from a therapeutic standpoint, these ULK1 inhibitors, which lead to both cytotoxicity (through Aurora A inhibition, among others) and to inhibition of autophagy as a survival pathway (through ULK1/2 inhibition), may be a novel and effective approach in cancer therapy.
Autophagy is a complex cellular process that is regulated on many levels and has been implicated in the development of a large diversity of diseases. To explore the potential of this process for the development of new treatment strategies, we presented here several high-resolution structural models of the key autophagy inducing kinases ULK1 and ULK2. These structures can now be used for the rational design of highly potent and selective chemical ULK1/2 probes for functional cellular studies. Screening a diverse kinase focused library we identified diverse chemical starting points for inhibitor development. In addition, we identified Aurora A kinase as a major off-target of currently used and available ULK1/2 inhibitors. Autophagic flux assays revealed that Aurora A inhibition by selective Aurora A inhibitors strongly induced autophagy counteracting the inhibitory effects expected by ULK1/2 inhibition. At higher compound concentration, however, inhibitory effects on autophagic flux were observed for the most potent ULK1/2 inhibitors. The data demonstrate that for more detailed mechanistic studies, ULK1/2 inhibitors with improved selectivity would be desirable, which forms a current research focus in our laboratories.
The co-ordinates and structure factors of all complexes have been deposited to the protein data bank under accession codes 6QAS, 6QAT, 6QAU and 6QAV.
acute myeloid leukemia
autophagy-related protein 1
autophagy-related protein 13
autophagy-related protein 101
Checkpoint kinase 2
death-associated protein kinase 3
RB (retinoblastoma) 1-inducible coiled-coil protein 1
STE20-like serine/threonine-protein kinase
Unc-51-like autophagy activating kinase 1
Unc-51-like autophagy activating kinase 2
A.C., C.H.B. and S.K. designed research. A.C. performed crystallographic, biochemical and inhibitor-binding study. Cellular inhibition study was performed by S.E.K. and S.S. for AML cell lines, and A.S., K.Z. and C.P. for RPE1 cells. H.R., L.J.L. and N.D.P.C. performed ADP-Glo assays. A.C. and S.K. wrote the manuscript, which was approved by all authors.
A.C. and S.K. are grateful for the support received from SGC, a registered charity [number 1097737] that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, São Paulo Research Foundation-FAPESP, Takeda and the Wellcome Trust [106169/ZZ14/Z]. We are grateful to the DFG funded ‘center of excellence’ (CEF, to S.K.), the Collaborative Sonderforschungsbereich 1177 Autophagy [SFB1177, to A.C., A.S., C.H.B. and S.K.] at Frankfurt University, as well as the German Cancer Consortium (DKTK to C.H.B. and S.K.), the Deutsche José Carreras Leukämie-Stiftung (DJCLS R14/14 to S.S. and C.H.B.) and the Else Kröner-Forschungskolleg (to S.S.). H.R., L.J.L. and N.D.P.C. are grateful for support from the Epstein Foundation and NCI CCSG (P30CA030199).
The authors thank staffs at BESSY II and SLS for their support during crystallographic X-ray diffraction test and data collection. The data collection at SLS has been supported by the funding from the European Union's Horizon 2020 Research and Innovation program under grant agreement number 730872, project CALIPSOplus.
The Authors declare that there are no competing interests associated with the manuscript.